Uehara Ritei, Belay Ermias D, Maddox Ryan A, Holman Robert C, Nakamura Yosikazu, Yashiro Mayumi, Oki Izumi, Ogino Hirotaro, Schonberger Lawrence B, Yanagawa Hiroshi
The Division of Viral and Rickettsial Diseases, National Center for Zoonotic Vector-Borne and Enteric Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
Pediatr Infect Dis J. 2008 Feb;27(2):155-60. doi: 10.1097/INF.0b013e31815922b5.
Some Kawasaki disease (KD) patients do not respond to initial treatment with intravenous immunoglobulin (IVIG). The purpose of this study was to determine potential risk factors associated with IVIG nonresponse among KD patients in Japan.
Data were obtained from questionnaires used for the 18th nationwide KD survey of patients who visited hospitals in Japan from 2003 through 2004. Data for patients who met the case definition for KD and received 2 g/kg single infusion IVIG as the initial treatment within 10 days of illness were analyzed. IVIG nonresponders were defined as patients who needed secondary treatment after initial IVIG administration.
Among 15,940 KD patients in Japan during 2003-2004, 6330 patients received 2 g/kg single infusion IVIG within 10 days of illness onset. IVIG nonresponders accounted for 20.3% of them (n = 1286). Male sex [odds ratio (OR), 1.21, 95% confidence interval (CI), 1.06-1.37], receipt of the initial IVIG before the fifth day of illness (OR: 1.89, 95% CI: 1.66-2.15), and having recurrent KD (OR: 1.38, 95% CI: 1.00-1.90) were significantly associated with IVIG nonresponse. In addition, IVIG nonresponders had significantly higher risks for coronary artery aneurysms (OR: 10.38, 95% CI: 6.98-15.45) or giant coronary artery aneurysms (OR: 54.06, 95% CI: 12.84-227.65).
Physicians should consider potential IVIG nonresponse among recurrent KD patients or KD patients diagnosed and treated before the fifth day of illness, particularly if they are boys and have laboratory values associated with nonresponse such as low platelet count, and elevated alanine aminotransferase and C-reactive protein. Some of these patients may benefit from administration of the alternative secondary treatment early during the illness along with the initial IVIG treatment.
一些川崎病(KD)患者对静脉注射免疫球蛋白(IVIG)的初始治疗无反应。本研究的目的是确定日本KD患者中与IVIG无反应相关的潜在风险因素。
数据来自于2003年至2004年期间对日本医院就诊的患者进行的第18次全国性KD调查所使用的问卷。分析符合KD病例定义且在发病10天内接受2g/kg单次静脉注射IVIG作为初始治疗的患者的数据。IVIG无反应者定义为在初始IVIG给药后需要二次治疗的患者。
在2003 - 2004年期间日本的15940例KD患者中,6330例患者在发病10天内接受了2g/kg单次静脉注射IVIG。IVIG无反应者占其中的20.3%(n = 1286)。男性[比值比(OR),1.21,95%置信区间(CI),1.06 - 1.37]、在发病第5天之前接受初始IVIG治疗(OR:1.89,95% CI:1.66 - 2.15)以及患有复发性KD(OR:1.38,95% CI:1.00 - 1.90)与IVIG无反应显著相关。此外,IVIG无反应者发生冠状动脉瘤(OR:10.38,95% CI:6.98 - 15.45)或巨大冠状动脉瘤(OR:54.06,95% CI:12.84 - 227.65)的风险显著更高。
医生应考虑复发性KD患者或在发病第5天之前确诊并接受治疗的KD患者中潜在的IVIG无反应情况,特别是如果他们是男孩且具有与无反应相关的实验室值,如血小板计数低、丙氨酸转氨酶和C反应蛋白升高。这些患者中的一些可能在疾病早期与初始IVIG治疗同时接受替代二次治疗会受益。